Svb Leerink Research Analysts Lower Earnings Estimates for DBV TECHNOLOGIE/S (DBVT)

DBV TECHNOLOGIE/S (NASDAQ:DBVT) – Research analysts at Svb Leerink lowered their FY2019 earnings estimates for DBV TECHNOLOGIE/S in a report released on Monday, March 11th. Svb Leerink analyst J. Schwartz now anticipates that the company will post earnings of ($6.65) per share for the year, down from their previous forecast of ($2.99). Svb Leerink also issued estimates for DBV TECHNOLOGIE/S’s FY2020 earnings at ($5.53) EPS, FY2021 earnings at ($1.10) EPS, FY2022 earnings at ($1.18) EPS and FY2023 earnings at ($0.22) EPS.

A number of other equities analysts have also recently commented on DBVT. Zacks Investment Research upgraded DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a report on Friday, November 16th. BidaskClub cut DBV TECHNOLOGIE/S from a “sell” rating to a “strong sell” rating in a report on Friday, November 23rd. Jefferies Financial Group cut DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating and set a $5.25 price target for the company. in a report on Thursday, December 20th. Barclays cut DBV TECHNOLOGIE/S from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $30.00 to $8.00 in a report on Thursday, December 20th. Finally, Stifel Nicolaus cut DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating and set a $11.00 price target for the company. in a report on Thursday, December 20th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $17.92.

DBV TECHNOLOGIE/S stock opened at $8.22 on Thursday. DBV TECHNOLOGIE/S has a 52 week low of $3.60 and a 52 week high of $25.77. The stock has a market cap of $512.97 million, a P/E ratio of -2.47 and a beta of 1.98.

Large investors have recently modified their holdings of the company. FMR LLC boosted its holdings in shares of DBV TECHNOLOGIE/S by 1.4% during the third quarter. FMR LLC now owns 1,325,676 shares of the company’s stock worth $29,775,000 after acquiring an additional 18,744 shares during the period. Perceptive Advisors LLC boosted its holdings in shares of DBV TECHNOLOGIE/S by 42.8% during the third quarter. Perceptive Advisors LLC now owns 3,009,998 shares of the company’s stock worth $67,604,000 after acquiring an additional 901,800 shares during the period. First Midwest Bank Trust Division boosted its stake in shares of DBV TECHNOLOGIE/S by 505.4% in the fourth quarter. First Midwest Bank Trust Division now owns 988,891 shares of the company’s stock valued at $6,349,000 after buying an additional 825,533 shares during the period. Exane Asset Management boosted its stake in shares of DBV TECHNOLOGIE/S by 30.0% in the third quarter. Exane Asset Management now owns 65,000 shares of the company’s stock valued at $1,460,000 after buying an additional 15,000 shares during the period. Finally, BlackRock Inc. boosted its stake in shares of DBV TECHNOLOGIE/S by 0.9% in the third quarter. BlackRock Inc. now owns 312,261 shares of the company’s stock valued at $7,014,000 after buying an additional 2,741 shares during the period. Institutional investors own 44.00% of the company’s stock.

DBV TECHNOLOGIE/S Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Further Reading: The risks of owning bonds

Earnings History and Estimates for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.